LON:RENE ReNeuron Group (RENE) Share Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free RENE Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 3.38▼ 4.1552-Week Range N/AVolume177,373 shsAverage Volume578,249 shsMarket Capitalization£1.93 millionP/E RatioN/ADividend Yield0.76%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Get ReNeuron Group alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About ReNeuron Group Stock (LON:RENE)ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now RENE Stock News HeadlinesMarch 28, 2024 | lse.co.ukUpland Resources shares soar as company prepares for Sarawak drillingMarch 23, 2024 | americanbankingnews.comReNeuron Group (LON:RENE) Stock Price Crosses Below 200 Day Moving Average of $4.71March 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 22, 2024 | msn.comCompany given millions of public money in Welsh Gov's disastrous foray into biotech investments collapses into administrationMarch 20, 2024 | lse.co.ukTRADING UPDATES: ReNeuron appoints administrators as rescue talks failFebruary 21, 2024 | morningstar.comReNeuron Group PLC RENEFebruary 19, 2024 | lse.co.ukTrident Royalties secures USD40 million revolving credit facilityFebruary 5, 2024 | lse.co.ukTRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash returnMarch 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 5, 2024 | msn.comReneuron issues administration warning as biotech firm puts jobs at riskNovember 8, 2023 | lse.co.ukReNeuron interim loss narrows on lower costs; eyes partnershipsSeptember 18, 2023 | finance.yahoo.comReNeuron Group plc (LON:RENE): Is Breakeven Near?May 19, 2023 | finance.yahoo.comReNeuron Group Slides As Insider Purchases Lose Another UK£75kMay 19, 2023 | finance.yahoo.comReNeuron Group Slides As Insider Purchases Lose Another UK£75k \May 16, 2023 | marketwatch.com2023 Neuronal Cell Culture Media Market Size and Research Report in Medical Devices & Consumables Sector | with [104 Pages] and Forecast till 2031May 13, 2023 | marketwatch.comGlobal Retinitis Pigmentosa Treatment & Management Market Report 2023-2030: Top Growth Opportunities and TrendsApril 27, 2023 | marketwatch.comCritical Limb Ischemia Drug Market Size by 2031April 20, 2023 | marketwatch.comPlacental Stem Cell Therapy Market [2023-2030]: Detailed Growth AnalysisApril 7, 2023 | marketwatch.comStem Cell Therapy Market Size, Revenue, and Forecast 2030March 28, 2023 | uk.finance.yahoo.comGlobal Market for Stem Cells 2023: Potential as Disease Treatment Options Fuels Market MomentumMarch 21, 2023 | uk.finance.yahoo.comGlobal Market for Stem CellsMarch 13, 2023 | proactiveinvestors.comReNeuron to present at Advanced Therapies 2023 conferenceFebruary 13, 2023 | proactiveinvestors.comReNeuron Group’s investment potential ‘remains intact’, 2024 cash runway secured, says LiberumJanuary 19, 2023 | marketwatch.comReNeuron Group Cuts 40% of Staff, Cash Extended into 2024January 5, 2023 | marketwatch.comRetinitis Pigmentosa (Retinitis) Market Massive Growth Strikes Due To Technological Innovation During 2023-2028January 3, 2023 | proactiveinvestors.comReNeuron Group PLC: Chairman takes the reins as CEO steps downJanuary 3, 2023 | proactiveinvestors.comReNeuron Group: chairman takes the reins as CEO steps downSee More Headlines Receive RENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/20/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:RENE CUSIPN/A CIKN/A Webwww.reneuron.com Phone+44-20-38198400FaxN/AEmployees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E Ratio0.47 P/E GrowthN/ANet Income£-5,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-106.77% Return on Assets-37.91% Debt Debt-to-Equity Ratio14.25 Current Ratio1.51 Quick Ratio2.02 Sales & Book Value Annual Sales£783,000.00 Price / Sales2.46 Cash FlowGBX 5.55 per share Price / Cash Flow0.61 Book ValueGBX 4 per share Price / Book0.84Miscellaneous Outstanding Shares57,170,000Free FloatN/AMarket Cap£1.93 million OptionableNot Optionable Beta0.92 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Iain Gladstone Ross B.Sc. (Age 70)BSc (Hons), C.DIR, CH.D, Executive Chairman Comp: $430kMr. John Michael Hawkins A.C.A. (Age 58)Company Secretary, CFO & Director Comp: $192.91kDr. John David Sinden B.A. (Age 73)BA, M.A., MA, Ph.D., Co-Founder Comp: $103kMs. Suzanne HancockChief Operations OfficerDr. Randolph Corteling Ph.D.Chief Scientific OfficerMr. Simon DewChief Business OfficerMore ExecutivesKey CompetitorsPhysiomicsLON:PYCSalvaRx GroupLON:SALVNuformixLON:NFXEvgen PharmaLON:EVGAptamer GroupLON:APTAView All CompetitorsInsidersJohn HawkinsBought 52,332 shares on 7/12/2023Total: £470,988.00 ($9.00/share)Iain G RossBought 150,000 shares on 6/16/2023Total: £1.20 M ($8.00/share)Barbara StaehelinBought 50,000 shares on 4/6/2023Total: £450,000.00 ($9.00/share)View All Insider Transactions RENE Stock Analysis - Frequently Asked Questions How were ReNeuron Group's earnings last quarter? ReNeuron Group plc (LON:RENE) released its earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, topping analysts' consensus estimates of ($50.20) by $14.30. What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR), Sirius Minerals (SXX), Collagen Solutions plc (COS.L) (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF). How do I buy shares of ReNeuron Group? Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:RENE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReNeuron Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.